A Multicenter, Randomized, Double-Blind, Parallel-Group Dose-Controlled Study Evaluating the Safety and Efficacy of RE104 for Injection in the Treatment of Patients With Postpartum Depression (PPD)

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 24 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

07 Apr 2025 According a Reunion Neuroscience media release, company anticipates to present Initial data from RECONNECT are expected in mid-2025.
04 Mar 2025 According a Reunion Neuroscience media release, company will present on RE104 and the RECONNECT Phase 2 clinical trial as part of a panel discussion, "New Treatment Options", at the 2025 Maternal Mental Health FORUM taking place virtually March 18-19, 2025.
09 Oct 2024 According a Reunion Neuroscience media release, the company has partnered with the Seleni Institute, a New York City based nonprofit, to support the broader maternal mental health community with the advancement of Phase 2 RECONNECT trial evaluating RE104 in adult female patients with moderate-to-severe PPD.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com